Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29849180 | 0.91 | HDAC7 (0.55) | HDAC7CHRM3PTGDR2L3MBTL1MEN1 | |
| SCHEMBL18415471 | 0.91 | HDAC7 (0.55) | HDAC7CHRM3PTGDR2L3MBTL1MEN1 | |
| SCHEMBL11187279 | 0.90 | HDAC7 (0.54) | HDAC7CHRM3PTGDR2L3MBTL1MEN1 | |
| SCHEMBL28806047 | 0.90 | HDAC7 (0.54) | HDAC7CHRM3PTGDR2L3MBTL1MEN1 | |
| SCHEMBL3906980 | 0.86 | HDAC7 (0.53) | HDAC7PTGDR2L3MBTL1MEN1KMT2A | |
| SCHEMBL25350383 | 0.85 | HDAC7 (0.50) | HDAC7CHRM3PTGDR2L3MBTL1MEN1 | |
| SCHEMBL28468828 | 0.84 | HDAC7 (0.49) | HDAC7CHRM3PTGDR2L3MBTL1MEN1 | |
| SCHEMBL16438547 | 0.84 | CHRM3 (0.56) | CHRM3SMN1; SMN2MAPT | |
| SCHEMBL3970097 | 0.84 | MEN1 (0.50) | CHRM3L3MBTL1MEN1KMT2AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5099217 | 0.82 | AKR1C3 (0.41) | HDAC7CHRM3L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3029026-B1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG A ST CO LTD (KR) | 2018-12-05 | — | — | EP | claimed |
| US-9828339-B2 | Biphenyl derivatives and methods for preparing same | DONG-A ST CO., LTD (KR) | 2017-11-28 | — | — | US | claimed |
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG-A ST CO., LTD (KR) | 2016-06-23 | — | — | US | claimed |
| EP-3029026-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | claimed |
| EP-3029026-B1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG A ST CO LTD (KR) | 2018-12-05 | — | — | EP | disclosed |
| US-9828339-B2 | Biphenyl derivatives and methods for preparing same | DONG-A ST CO., LTD (KR) | 2017-11-28 | — | — | US | disclosed |
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG-A ST CO., LTD (KR) | 2016-06-23 | — | — | US | disclosed |
| EP-3029026-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | disclosed |
| EP-3029026-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015016511-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | 동아에스티 주식회사 (KR) | 2015-02-05 | — | — | WO | disclosed |
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | LAINE DRAMANE I | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | CHRM2, CHRM3, CHRM5 | HDAC7 2201/4885CHRM3 2/4885PTGDR2 1032/4885 |
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | HDAC7 2218/4885CHRM3 1/4885PTGDR2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.